<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>YOBINE- yohimbine hydrochloride injection, solution </strong><br>Akorn Animal Health, Inc.<br></p></div>
<h1>Yobine<span class="Sup">®</span> Injection
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">(Yohimbine Sterile Solution)<br>2.0 mg/mL<br>Xylazine Reversing Agent and Antidote<br>For Use in Dogs Only
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CAUTION:
</h1>
<p class="First">Federal law restricts this drug to use by or on the order of a licensed veterinarian.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>Description:
</h1>
<p class="First">Yobine<span class="Sup">®</span> contains yohimbine with the chemical name 17 alpha-hydroxy-20 alpha-yohimban-16 beta-carboxylic acid methyl ester. Yohimbine hydrochloride has a molecular weight of 390.89, and the molecular formula is C<span class="Sub">21</span>H<span class="Sub">26</span>N<span class="Sub">2</span>O<span class="Sub">3</span>•HCI. The structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a43d4-8b9f-4bc3-a6b8-a7418fdb4626&amp;name=yob00-0000-01.jpg">
</div>
<p>Each mL contains: Yohimbine (as the hydrochloride) 2.0 mg, methylparaben 0.9 mg, propylparaben 0.1 mg, citric acid 3.34 mg, and water for injection, pH adjusted with sodium hydroxide.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>PHARMACOLOGY:
</h1>
<p class="First">Yohimbine is an indolealkylamine alkaloid that acts primarily by blocking central alpha-2 adrenoreceptors that are stimulated by xylazine. Yohimbine is an alpha-2 adrenergic receptor antagonist that easily penetrates the blood-brain barrier. It competitively blocks and antagonizes central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or sedation and the <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> caused by xylazine.
</p>
<p>Xylazine, an alpha-2 adrenergic agonist with potent sedative, analgesic and muscle relaxant properties, has been used extensively as an analgesic-sedative restraining agent. It has also been used as a preanesthetic agent for many general anesthetics. The central nervous system depressant effect, as well as other pharmacologic effects, is dose dependent.
</p>
<p>Yohimbine is useful to counteract the sedation after standard doses of xylazine. The competitive selective blocking of the alpha-2 adrenergic receptor by yohimbine displaces xylazine from these sites and thereby rapidly cancels the effect of the xylazine.
</p>
<p>Yohimbine, when used at the prescribed dose, will effectively reverse the effects of xylazine when it is used alone in dogs. Yohimbine abbreviates the anesthesia and chemical restraint of the xylazine.
</p>
<p>The reversal of the sedative effects of xylazine by I.V. injection of yohimbine is rapid, usually occurring within one to three minutes, regardless of the route of administration of xylazine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS:
</h1>
<p class="First">Yohimbine should be used in dogs when it is desirable to reverse the effects of xylazine. Yohimbine has been used successfully to reverse the sedative effects of xylazine and to reverse the cardiac effects of xylazine such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> when xylazine is administered alone.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:
</h1>
<p class="First">For intravenous injection. The usual dose is 0.5 mL/20 lb body weight (0.05 mg/lb, or 0.11 mg/kg) to reverse the sedative effects of xylazine. The carefully calculated dose of yohimbine should be given intravenously slowly.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>SIDE EFFECTS:
</h1>
<p class="First">Occasionally a dog that has been reversed will show signs of apprehensiveness but this state quickly subsides.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS:
</h1>
<p class="First">The safety of yohimbine in pregnant dogs or in dogs intended for breeding has not been established.
</p>
<p>Careful consideration should be given before administering to dogs known to be epileptic or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> prone. The drug reverses the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of xylazine as well as the sedative effects. If the animal was given xylazine for its analgesic properties, reversal may result in return of normal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> perception.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-9"></a><p></p>
<h1>SAFETY:
</h1>
<p class="First">Yobine<span class="Sup">®</span> was tolerated in dogs at 3 times (0.15 mg/lb) and 5 times (0.25 mg/lb) the recommended dose administered without xylazine at 3 intervals of 6 hours. Dose at the 5x magnitude occasionally produced brief <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and muscle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> but no lasting untoward effects were observed.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s10"></a><a name="section-10"></a><p></p>
<h1>WARNING:
</h1>
<p class="First">Not for human use. This drug should not be administered to food-producing animals.
</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s11"></a><a name="section-11"></a><p></p>
<h1>STORAGE:
</h1>
<p class="First">Protect from heat and light. Do not store over 30°C (86°F).
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s12"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED:
</h1>
<p class="First">20 mL multiple-dose vial.
</p>
<p>NDC 59399-115-20
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s13"></a><a name="section-13"></a><p></p>
<h1>REFERENCES:
</h1>
<ol class="Arabic">
<li>Short, C.E., Ed: <span class="Bold">Principles and Practice of Veterinary Anesthesia</span>, Williams and Wilkens, Baltimore, MD, 1987.
</li>
<li>Hsu, WH. Xylazine-lnduced <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Its Antagonism by Alpha Adrenergic Blocking Agents. <span class="Bold">The Journal of Pharmacology and Experimental Therapeutics</span>. Vol. 218, No. 1, (188-192), 1981.
</li>
<li>Hatch, RC, et al. Antagonism of Xylazine Sedation with Yohimbine, 4-Aminopyridine, and Doxapram in Dogs. <span class="Bold">American Journal of Veterinary Research</span>. Vol. 46, No. 2, (371-375), 1985.
</li>
<li>Vet-A-Mix Research
</li>
</ol>
<p class="First"><span class="Bold">AKORN<br>Animal Health<br></span>Manufactured by:<br><span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p>YO00N       Rev. 07/14
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s14"></a><a name="section-14"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 59399-115-20
</p>
<p>Yobine<span class="Sup">®</span></p>
<p>INJECTION
</p>
<p>Yohimbine Sterile Solution 2 mg/mL
</p>
<p>Xylazine Reversing Agent and
</p>
<p>Antidote for Use in Dogs Only
</p>
<p>20 mL
</p>
<p>CAUTION: Federal law restricts this drug to use
</p>
<p>by or on the order of a licensed veterinarian.
</p>
<p>NADA #140-866, Approved by FDA
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a43d4-8b9f-4bc3-a6b8-a7418fdb4626&amp;name=yob00-0000-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s15"></a><a name="section-15"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 59399-115-20
</p>
<p>Yobine<span class="Sup">®</span></p>
<p>INJECTION
</p>
<p>Yohimbine Sterile
</p>
<p>Solution 2 mg/mL
</p>
<p>Xylazine Reversing Agent
</p>
<p>and Antidote for Use
</p>
<p>in Dogs Only
</p>
<p>20 mL
</p>
<p>CAUTION: Federal law restricts
</p>
<p>this drug to use by or on the
</p>
<p>order of a licensed veterinarian.
</p>
<p>Akorn Animal Health Logo
</p>
<p>NADA #140-866, Approved by FDA
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=479a43d4-8b9f-4bc3-a6b8-a7418fdb4626&amp;name=yob00-0000-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>YOBINE 		
					</strong><br><span class="contentTableReg">yohimbine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59399-115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Yohimbine Hydrochloride</strong> (Yohimbine) </td>
<td class="formItem">Yohimbine</td>
<td class="formItem">2.0 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem">0.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Propylparaben</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem">3.34 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59399-115-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA140866</td>
<td class="formItem">02/25/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn Animal Health, Inc.
							(078876357)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc</td>
<td class="formItem"></td>
<td class="formItem">603980319</td>
<td class="formItem">MANUFACTURE, ANALYSIS, STERILIZE, PACK, LABEL</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8b7d28ef-cffa-4f4d-8325-5598d8835810</div>
<div>Set id: 479a43d4-8b9f-4bc3-a6b8-a7418fdb4626</div>
<div>Version: 1</div>
<div>Effective Time: 20150226</div>
</div>
</div> <div class="DistributorName">Akorn Animal Health, Inc.</div></p>
</body></html>
